Acumen Pharmaceuticals Q3 2026 Earnings Date & Estimates

Acumen Pharmaceuticals (NASDAQ:ABOS) is a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer’s disease. The company’s research is based on the amyloid-beta oligomer hypothesis, which holds that soluble forms of amyloid-beta may contribute to the synaptic dysfunction and neurodegeneration associated with the disease.

Acumen’s lead product candidate is sabirnetug, also known as ACU193, an investigational humanized monoclonal antibody designed to selectively target toxic soluble amyloid-beta oligomers while seeking to avoid binding to monomeric amyloid-beta. The therapy is being evaluated for its potential to slow or modify the progression of early Alzheimer’s disease.

Founded in 1996 and headquartered in Charlottesville, Virginia, Acumen has advanced its programs through clinical development and collaborates with research institutions and clinical sites in support of its Alzheimer’s disease studies. As a clinical-stage company, Acumen’s pipeline remains centered on the research and development of disease-modifying therapies rather than marketed pharmaceutical products.